Edition:
United Kingdom

Shionogi & Co Ltd (4507.T)

4507.T on Tokyo Stock Exchange

6,180JPY
3:29am BST
Change (% chg)

¥37 (+0.60%)
Prev Close
¥6,143
Open
¥6,148
Day's High
¥6,198
Day's Low
¥6,143
Volume
411,100
Avg. Vol
1,177,259
52-wk High
¥6,465
52-wk Low
¥5,200

Latest Key Developments (Source: Significant Developments)

Shionogi Announces FDA Approval Of Mulpleta (Lusutrombopag)
Wednesday, 1 Aug 2018 

Aug 1 (Reuters) - Shionogi & Co Ltd <4507.T>::SHIONOGI ANNOUNCES FDA APPROVAL OF MULPLETA® (LUSUTROMBOPAG).SHIONOGI - FDA APPROVED MULPLETA FOR TREATMENT OF THROMBOCYTOPENIA IN ADULT PATIENTS WITH CHRONIC LIVER DISEASE SCHEDULED TO UNDERGO A PROCEDURE.  Full Article

Shionogi & Co Ltd Says To Buy Back Up To 2.7 Percent Of Own Shares Worth 50 Billion Yen
Monday, 30 Jul 2018 

July 30 (Reuters) - Shionogi & Co Ltd <4507.T>::SHIONOGI & CO LTD SAYS TO BUY BACK UP TO 2.7 PERCENT OF OWN SHARES WORTH 50 BILLION YEN.  Full Article

Shionogi & Co Regains Full Rights To Symproic In US
Monday, 9 Jul 2018 

July 9 (Reuters) - Shionogi & Co Ltd <4507.T>::SHIONOGI REGAINS FULL RIGHTS TO SYMPROIC (NALDEMEDINE) IN US.EFFECTIVE IMMEDIATELY, SHIONOGI HAS REGAINED FULL RIGHTS TO SYMPROIC (NALDEMEDINE) TABLETS 0.2 MG IN UNITED STATES.CO HAS BEGUN OWN SALES AND DISTRIBUTION OF SYMPROIC, IN PROCESS OF SEEKING A NEW PARTNER WITH STRONG COMMERCIAL CAPABILITIES.SHIONOGI AND PURDUE PHARMA LP HAVE AGREED TO TERMINATE PRIOR ALLIANCE FOR U.S. CO-COMMERCIALIZATION OF SYMPROIC.SHIONOGI HAS NO RESIDUAL FINANCIAL OR OTHER OBLIGATIONS TO PURDUE.  Full Article

ROHTO PHARMACEUTICAL says capital alliance with SHIONOGI HEALTHCARE
Monday, 25 Jun 2018 

June 25 (Reuters) - ROHTO PHARMACEUTICAL Co Ltd <4527.T> ::Says it signed an agreement with SHIONOGI HEALTHCARE & Co Ltd, to form a capital alliance .Says the company will acquire around 15 percent stake in SHIONOGI HEALTHCARE from its parent company SHIONOGI & CO LTD <<<4507.T>>>.  Full Article

PeptiDream says completion of technology transfer of Peptide Discovery Platform System to Shionogi
Thursday, 17 May 2018 

May 17 (Reuters) - PeptiDream Inc <4587.T>:Says co completed the transfer of co's proprietary Peptide Discovery Platform System (PDPS) technology to Shionogi & Co Ltd <<<4507.T>>>.Under the terms of the nonexclusive license agreement entered into by the co and Shionogi in June 2017, co will receive an undisclosed milestone payment and is eligible to receive additional technology access payments, in addition to payments based on achievement of certain predetermined development milestones for any constrained peptides and/or small molecules discovered from use of the PDPS technology.In addition, co is eligible to receive royalties on sales of certain products that arise from use of the PDPS technology .  Full Article

Shionogi to set up manufacturing unit
Monday, 23 Apr 2018 

April 23 (Reuters) - Shionogi & Co Ltd <4507.T>:Says it plans to set up a wholly owned manufacturing unit on Oct. 1.Says the unit will start business on April 1, 2019.Other details will be decided later.  Full Article

Shionogi completes retirement of treasury shares
Monday, 12 Mar 2018 

March 12(Reuters) - Shionogi & Co Ltd <4507.T>:Says it completed retirement of 5 million shares (1.5 percent stake) of its common stock on March 12.  Full Article

R&I affirms Shionogi & Co Ltd's rating at "A+" and says stable outlook-R&I
Friday, 15 Dec 2017 

Dec 15 (Reuters) - Shionogi & Co Ltd <4507.T> ::Rating and Investment Information, Inc. (R&I) affirmed the company's rating at "A+" -R&I.Rating outlook stable -R&I.  Full Article

Shionogi to repurchase shares and retire treasury shares
Monday, 27 Nov 2017 

Nov 27 (Reuters) - Shionogi & Co Ltd <4507.T>:Says it will repurchase up to 4.8 million shares, representing 1.5 percent of outstanding.Says share repurchase price at up to 30 billion yen in total.Says repurchase period from Dec. 1 to Feb. 28, 2018.Says it will retire 5 million shares of its common stock on March 12, 2018 .  Full Article

UMN Pharma says business and capital alliance with Shionogi
Tuesday, 31 Oct 2017 

Oct 31 (Reuters) - UMN Pharma Inc <4585.T>:Says it signed business and capital alliance agreement with Shionogi & Co Ltd <<<4507.T>>> on Oct. 31 .Says two entities will mainly cooperate on establishment of technological basis for drug discovery related to preventive vaccines against infectious diseases .Says it will issue 600,000 shares and first series convertible bonds with subscription warrants to Shionogi & Co Ltd, to raise 1.64 billion yen in total .Payment date on Nov. 16 .  Full Article

U.S. FDA approves blood disorder drug made by Japan's Shionogi

July 31 The U.S. Food and Drug Administration on Tuesday approved Japan-based Shionogi & Co Ltd's treatment for low blood-platelet count or thrombocytopenia in patients with chronic liver disease.